This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The serine kinase IKKb has been demonstrated to be a downstream mediator of insulin resistance through inhibition of the insulin receptor substrate and activation of inflammation via NF-kB. High doses of salicylates (aspirin) inhibit IKKb in rodents and improve glucose metabolism in type 2 diabetic (T2D) patients. In contrast to aspirin, salsalate is an equipotent inhibitor of NF-kB but not associated with risk of bleeding. The purpose of this study is to determine the effects of salicylates on inflammation targeting the IKKbeta/Nfkappa B pathway, in a population at risk for development of type 2 diabetes and hyperlipidemia. The study population is young, obese, individuals, ages 18-30, and the study design is a double-blinded placebo controlled, to determine the effects of one month of Salsalate on glycemia, insulin and C-peptide production and inflammatory markers.
Showing the most recent 10 out of 642 publications